Literature DB >> 6286790

Antibody response to varicella-zoster virus after natural or vaccine-induced infection.

S Bogger-Goren, K Baba, P Hurley, H Yabuuchi, M Takahashi, P L Ogra.   

Abstract

The development of serum and nasopharyngeal antibody responses to varicella-zoster virus (VZV) was studied in groups of children after naturally acquired varicella or after immunization with the Oka strain of live attenuated VZV vaccine administered in varying doses via respiratory inhalation or subcutaneous injection. Natural infection, subcutaneous immunization, and respiratory inhalation of large doses of VZV vaccine consistently resulted in the development of VZV-specific IgG antibody responses in serum. Although the serum IgG antibody responses persisted for at least eight to 12 months (to date) after either form of infection, the antibody activity appeared to be four- to eight-fold higher after natural infection than after immunization. Transient IgG antibody responses were observed in serum after respiratory inhalation of smaller doses of VZV vaccine. Natural infection, but not VZV vaccine, was associated with the development of serum and nasopharyngeal IgA responses to VZV in most subjects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6286790     DOI: 10.1093/infdis/146.2.260

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

Review 2.  Occupational hazards in hospitals: risk of infection.

Authors:  J J Gestal
Journal:  Br J Ind Med       Date:  1987-07

Review 3.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children.

Authors:  J A Englund; A M Arvin; H H Balfour
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

Review 5.  Varicella-zoster virus.

Authors:  A M Arvin
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

6.  Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenic.

Authors:  Toby M Ward; Vicki Traina-Dorge; Kara A Davis; Wayne L Gray
Journal:  J Gen Virol       Date:  2008-03       Impact factor: 3.891

7.  Antibody class capture assays for varicella-zoster virus.

Authors:  B Forghani; C K Myoraku; K W Dupuis; N J Schmidt
Journal:  J Clin Microbiol       Date:  1984-05       Impact factor: 5.948

8.  Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Gray; J Breuer; G Kafatos; S Parker; D Brown
Journal:  Clin Vaccine Immunol       Date:  2006-02

9.  Prevention and control of herpesvirus diseases. Part 2. Epidemiology and immunology.

Authors: 
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

10.  Serum immunoglobulin A antibody to varicella-zoster virus in subjects with primary varicella and herpes zoster infections and in immune subjects.

Authors:  A E Wittek; A M Arvin; C M Koropchak
Journal:  J Clin Microbiol       Date:  1983-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.